We congratulate Åslaug Helland!
Matrix is developing new diagnostic methods in molecular profiling (-omics), drug sensitivity screening, immune system characterization, Patient Reported Outcome Measures (PROMs) and Artificial Intelligence (AI) tools for analysis of images and clinical real-world data. The Centre collaborates closely with the national network for precision diagnostics (InPreD). This enables systematic and rapid testing of the clinical benefit of diagnostic tools in new clinical trials.
The Centre develops and tests new treatment strategies in clinical trials with an aim to contribute to an increased volume of precision medicine, patient-centred care, including symptom and function improvements as well as cell therapy studies in Norway. This applies not only to the final phase, but also in early lines of treatment. Patients from all of Norway should have the opportunity to participate in studies.
There is a need for tools that ensure that the patient's needs and preferences are integrated into treatment decisions. Matrix will develop and implement digital patient-centred care pathways, with evidence-based content that secures treatment and follow-up tailored to the individual patient. Matrix collaborates closely with the European Palliative Care Research Center and the EU-funded MyPath project.